Brief: Magenta Therapeutics Voluntarily Pauses Blood Cancer Therapy Trial To Investigate Drug Safety
25/01/2023 22:23
Jan 25 (Reuters) - Magenta Therapeutics Inc MGTA.O :
* MAGENTA THERAPEUTICS VOLUNTARILY PAUSES THE MGTA-117 PHASE
1/2
DOSE-ESCALATION CLINICAL TRIAL TO INVESTIGATE DRUG SAFETY
Source text for Eikon: ID:nGNX31Bp86
Further company coverage: MGTA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dianthus Therapeutics
See all newsU.S. RESEARCH ROUNDUP- Adobe, Chewy, Mosaic
Brief: Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
Dianthus Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Dianthus Therapeutics Q2 net loss widens as R&D costs rise